JPMorgan Chase & Co. Cuts Holdings in Ocular Therapeutix, Inc. (OCUL)

JPMorgan Chase & Co. decreased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 7.5% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 338,500 shares of the biopharmaceutical company’s stock after selling 27,325 shares during the period. JPMorgan Chase & Co. owned about 1.17% of Ocular Therapeutix worth $3,138,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Ocular Therapeutix by 24.0% in the 1st quarter. Vanguard Group Inc. now owns 902,262 shares of the biopharmaceutical company’s stock valued at $8,373,000 after acquiring an additional 174,688 shares in the last quarter. Teachers Advisors LLC lifted its stake in Ocular Therapeutix by 47.7% in the 4th quarter. Teachers Advisors LLC now owns 37,318 shares of the biopharmaceutical company’s stock valued at $312,000 after acquiring an additional 12,050 shares in the last quarter. Wellington Management Group LLP lifted its stake in Ocular Therapeutix by 35.2% in the 1st quarter. Wellington Management Group LLP now owns 1,312,703 shares of the biopharmaceutical company’s stock valued at $12,182,000 after acquiring an additional 341,767 shares in the last quarter. SG Americas Securities LLC bought a new stake in Ocular Therapeutix in the 1st quarter valued at approximately $455,000. Finally, Alps Advisors Inc. lifted its stake in Ocular Therapeutix by 5.9% in the 2nd quarter. Alps Advisors Inc. now owns 26,201 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 1,462 shares in the last quarter. Hedge funds and other institutional investors own 53.42% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://stocknewstimes.com/2017/10/11/jpmorgan-chase-co-cuts-holdings-in-ocular-therapeutix-inc-ocul.html.

Several research firms have commented on OCUL. Cantor Fitzgerald restated a “buy” rating and issued a $21.00 target price on shares of Ocular Therapeutix in a research note on Monday, September 25th. ValuEngine cut Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 21st. BTIG Research restated a “neutral” rating on shares of Ocular Therapeutix in a research note on Thursday, August 10th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Ocular Therapeutix in a research note on Wednesday, August 9th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $8.00 target price (down previously from $16.00) on shares of Ocular Therapeutix in a research note on Friday, July 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $24.00.

Shares of Ocular Therapeutix, Inc. (OCUL) opened at 6.08 on Wednesday. The company’s market cap is $176.66 million. The stock’s 50 day moving average price is $6.27 and its 200-day moving average price is $8.01. Ocular Therapeutix, Inc. has a 52 week low of $4.82 and a 52 week high of $11.91.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.05). The company had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.51 million. Ocular Therapeutix had a negative net margin of 3,005.52% and a negative return on equity of 101.03%. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.46) EPS. Analysts expect that Ocular Therapeutix, Inc. will post ($2.29) EPS for the current year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL).

Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply